JP2015522018A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522018A5
JP2015522018A5 JP2015520304A JP2015520304A JP2015522018A5 JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5 JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound according
acceptable salt
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015520304A
Other languages
English (en)
Japanese (ja)
Other versions
JP6127136B2 (ja
JP2015522018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/046684 external-priority patent/WO2014004229A1/en
Publication of JP2015522018A publication Critical patent/JP2015522018A/ja
Publication of JP2015522018A5 publication Critical patent/JP2015522018A5/ja
Application granted granted Critical
Publication of JP6127136B2 publication Critical patent/JP6127136B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015520304A 2012-06-29 2013-06-20 フェノキシエチルピペリジン化合物 Active JP6127136B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (3)

Publication Number Publication Date
JP2015522018A JP2015522018A (ja) 2015-08-03
JP2015522018A5 true JP2015522018A5 (index.php) 2016-08-04
JP6127136B2 JP6127136B2 (ja) 2017-05-10

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520304A Active JP6127136B2 (ja) 2012-06-29 2013-06-20 フェノキシエチルピペリジン化合物

Country Status (42)

Country Link
US (2) US8962659B2 (index.php)
EP (1) EP2867207B1 (index.php)
JP (1) JP6127136B2 (index.php)
KR (1) KR101653476B1 (index.php)
CN (1) CN104411684B (index.php)
AP (1) AP2014008164A0 (index.php)
AR (1) AR091429A1 (index.php)
AU (1) AU2013280875B2 (index.php)
BR (1) BR112014031616B1 (index.php)
CA (1) CA2875569C (index.php)
CL (1) CL2014003535A1 (index.php)
CO (1) CO7151507A2 (index.php)
CR (1) CR20140553A (index.php)
CY (1) CY1119425T1 (index.php)
DK (1) DK2867207T3 (index.php)
DO (1) DOP2014000287A (index.php)
EA (1) EA024392B1 (index.php)
EC (1) ECSP14033267A (index.php)
ES (1) ES2644812T3 (index.php)
GT (1) GT201400288A (index.php)
HR (1) HRP20171515T1 (index.php)
HU (1) HUE034425T2 (index.php)
IL (1) IL236219A (index.php)
JO (1) JO3296B1 (index.php)
LT (1) LT2867207T (index.php)
MA (1) MA37686B1 (index.php)
ME (1) ME02840B (index.php)
MX (1) MX345324B (index.php)
MY (1) MY173878A (index.php)
NZ (1) NZ701933A (index.php)
PE (1) PE20150182A1 (index.php)
PH (1) PH12015500009B1 (index.php)
PL (1) PL2867207T3 (index.php)
PT (1) PT2867207T (index.php)
RS (1) RS56452B1 (index.php)
SG (1) SG11201408641UA (index.php)
SI (1) SI2867207T1 (index.php)
TN (1) TN2014000501A1 (index.php)
TW (1) TWI599561B (index.php)
UA (1) UA114325C2 (index.php)
WO (1) WO2014004229A1 (index.php)
ZA (1) ZA201408632B (index.php)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
BR112016011016A8 (pt) 2013-12-17 2018-01-30 Lilly Co Eli derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica.
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
TWI765041B (zh) 2017-05-18 2022-05-21 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯基衍生物
US20200069686A1 (en) 2017-05-18 2020-03-05 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
WO2018210987A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
WO2018210992A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
EA201992677A1 (ru) 2017-05-18 2020-04-23 Идорсия Фармасьютиклз Лтд Пиримидиновые производные в качестве модуляторов pge2 рецепторов
JP7488269B2 (ja) * 2019-01-22 2024-05-21 キーセラ・(スーチョウ)・ファーマシューティカルズ・カンパニー・リミテッド Pge2/ep4シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ep4拮抗藥與免疫檢查點抑制物質而進行之癌症治療
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE60307607T2 (de) * 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
KR100752891B1 (ko) * 2003-01-10 2007-08-28 에프. 호프만-라 로슈 아게 프로스타글란딘 작용제로서 2-피페리돈 유도체
JP4116058B2 (ja) 2003-09-03 2008-07-09 ファイザー株式会社 プロスタグランジンe2拮抗薬としてのフェニルまたはピリジルアミド化合物
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
DE602005015215D1 (de) 2004-05-04 2009-08-13 Raqualia Pharma Inc Orthosubstituierte aryl- oder heteroarylamidverbindungen
AU2005238291A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドールアミド誘導体
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
JP6152643B2 (ja) 2010-02-22 2017-06-28 株式会社AskAt Il−23媒介疾患を治療するためのep4受容体拮抗薬の使用
UA113499C2 (xx) * 2010-09-21 2017-02-10 Фармацевтична композиція
WO2013004290A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor antagonists
US9120824B2 (en) * 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Similar Documents

Publication Publication Date Title
JP2015522018A5 (index.php)
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP2016508134A5 (index.php)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2016536286A5 (index.php)
JP2016527217A5 (index.php)
JP2015522589A5 (index.php)
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
SI2932970T1 (en) Antiviral therapy
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2016528301A5 (index.php)
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2014502641A5 (index.php)
JP2016522254A5 (index.php)
RU2016150326A (ru) Производные изоиндолина для применения в лечении вирусной инфекции
JP2016510326A5 (index.php)
JP2019505529A5 (index.php)
RU2017103656A (ru) Производные изоиндолинона, полезные в качестве противовирусных средств
JP2015522033A5 (index.php)
JP2015516419A5 (index.php)
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
RU2017134285A (ru) Борсодержащие низкомолекулярные соединения как антипротозойные агенты
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком